CD8A and cancer: More recently, LILRB1 blockade was shown to enhance cytotoxic CD8+ T cell activity using bispecific T cell engager (BiTE) (Kim et al., 2019) molecules, highlighting the potential of the LILRB1 receptor as an anti-cancer therapeutic target.